What is BlossomHill Therapeutics, Inc. (BLSM) stock price today?

BlossomHill Therapeutics, Inc. (BLSM) is currently trading at $17.48, up 3.55% today.

What is BLSM P/E ratio?

BlossomHill Therapeutics, Inc.'s P/E ratio is -1.85. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BLSM return on equity (ROE)?

BlossomHill Therapeutics, Inc.'s return on equity (ROE) is 127.76%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is BlossomHill Therapeutics, Inc.'s market cap?

BlossomHill Therapeutics, Inc. has a market capitalization of $508.34M.

NASDAQ · Biotechnology

BlossomHill Therapeutics, Inc. (BLSM) Stock

$17.48 +3.55% NASDAQ: BLSM Healthcare

Blossomhill Therapeutics, Inc. is a biopharmaceutical company.

Valuation

Metric	Value
Price	$17.48
Market Cap	$508.34M
P/E Ratio	-1.85
P/B Ratio	5.78
P/S Ratio	0.00
EPS (TTM)	$-2.08
52-Week High	$27.99
52-Week Low	$15.25
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	127.76%
ROA	-36.06%
ROCE	-44.33%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.28
Current Ratio	5.42

Annual Financials (USD)

Metric	2024	2025
Revenue	$0	$0
Operating Profit	$-36.0M	$-64.0M
Net Profit	$-31.0M	$-61.0M
EPS	$-1.06	$-2.08
Op Margin	—	—

Balance Sheet (USD)

Metric	2024	2025
Total Assets	$107.0M	$163.0M
Total Liabilities	$180.0M	$295.0M
Cash	$100.0M	$137.0M
Borrowings	$1.0M	$22.0M

Latest News

Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday MT Newswires · Aug 18, 2026 BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC GlobeNewswire · Aug 18, 2026 BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering GlobeNewswire · Aug 7, 2026

Cash Flow (USD)

Metric	2024	2025
Operating Cash Flow	$-31.0M	$-47.0M
Investing Cash Flow	$0	$-2.0M
Financing Cash Flow	$0	$1.0M
Net Cash Flow	$-14.0M	$37.0M
Free Cash Flow	$-32.0M	$-48.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.02
EV / EBITDA	-9.35
FCF Yield	-9.44%
Quick Ratio	5.42
Interest Coverage	0.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held13.18%

Institutions Held26.55%

Institutions Float Held30.58%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACTUActuate Therapeutics, Inc.	$0.61	-10.13%	-0.92	$14.60M	0.00%
AGIOAgios Pharmaceuticals, Inc.	$31.81	-0.34%	-4.54	$1.90B	0.00%
ALLRAllarity Therapeutics, Inc.	$0.99	+0.82%	-1.33	$15.75M	0.00%
AVBPArriVent BioPharma, Inc.	$16.73	+0.12%	-7.60	$779.20M	0.00%
FHTXFoghorn Therapeutics Inc.	$2.00	+0.50%	-2.11	$117.43M	0.00%

About BlossomHill Therapeutics, Inc.

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

BlossomHill Therapeutics, Inc. is led by CEO Jing Rong Jean Cui, headquartered in San Diego, US, publicly traded since 2026.

BlossomHill Therapeutics, Inc. (BLSM) stock trades at $17.48 with a market capitalization of $508.34M. The stock is valued at a price-to-earnings (P/E) ratio of -1.85, price-to-book of 5.78, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $15.25 and $27.99, and currently trades 37.5% below its 52-week high.

On profitability, BlossomHill Therapeutics, Inc. generates a return on equity (ROE) of 127.76% — well above the market average, a sign of a high-quality business, return on capital employed of -44.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.bhtherapeutics.com